Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Gregory S. Burzynski"'
Publikováno v:
Biomedical Research and Clinical Practice. 6
Publikováno v:
Journal of Cancer Therapy. :173-187
Despite dramatic progress over the last 50 years in the treatment of many childhood cancers, primary brain tumors remain the leading cause of death in pediatric oncology. This phase II study evaluated the efficacy and safety of Antineoplastons A10 an
Publikováno v:
Journal of Cancer Therapy. :40-44
Diffuse intrinsic pontine glioma (DIPG) is the most common type of brainstem glioma and one of the most deadly brain tumors. DIPG in young adult patients is a rare disease for which treatment options are limited. Radiation therapy remains the standar
Publikováno v:
Journal of Cancer Therapy. :1063-1074
Antineoplastons A10 and AS2-1 (ANP) are synthetic derivatives of glutamine, isoglutamine, and phenylacetic acid. In 1993, a phase II clinical trial program began according to protocols based on the initial protocol, BT-06, which was transferred from
Publikováno v:
Pediatric Neurosurgery. 50:99-103
Tectal glioma is a midbrain tumor. The patient generally presents with symptoms related to increased intracranial pressure and requires treatment for hydrocephalus. No effective pharmacological treatments have yet been introduced. This report discuss
Publikováno v:
Journal of Cancer Therapy. :334-344
Inoperable brainstem gliomas (BSG) are among the most difficult to treat malignancies. In the intent-to-treat (ITT) population of the BT-11 study for BSG, forty patients (median age 11.2 years old) were enrolled. Antineoplastons A10 and AS2-1 (ANP) w
Publikováno v:
Journal of Pediatric Hematology/Oncology
Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The authors describe the case of an unusual pontine location of GS in a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully control
Publikováno v:
Journal of Cancer Therapy. :565-577
Standard treatment for high-grade glioma involves surgical resection followed by radiation ther- apy and temozolomide. Unfortunately, there are no standard treatment recommendations after recurrence and new therapies are needed for patients whose tum
Publikováno v:
Journal of Cancer Therapy. :957-976
Recurrent GBM (RGBM) has a highly unfavorable prognosis with majority of patients dying within 6 months and no standard treatments available. Antineoplaston (ANP) A10 and AS2-1 injections underwent Phase II trials in RGBM patients, which reported a l
Publikováno v:
Journal of Cancer Therapy. :1072-1091
Metastatic pancreatic cancer carries an estimated five-year survival rate of only 2%. Gemcitabine-based chemotherapy remains a first-line standard-of-care treatment for elderly patients with advanced pancreatic cancer. Combination chemotherapy FOLFIR